intratio Posted - 7 hours ago

The algorithm is predicting that the price action of this stock has a clear poor short-term setup also clearly lacks long-term fundamentals $SNSE

LabPsycho Posted - 1 day ago

$SNSE @Selwot Furthermore, VINC did not have any recent or legacy publications any where near as impressive and SNSE's recent Nature Communication publication.

LabPsycho Posted - 1 day ago

$SNSE Okay...a preview. Molecular Dynamic Simulation of $SNSE VISTA:SNS-101-Fab complex at acid pH. Had to cram 50 Gb worth of info into a few Mb gif. Most important is first and last from. Antibody moves into postion on VISTA and forms bonds with key charge Histidine residues (that would not be charged in neutral environment. Very impressive and helps explain the specificity.

LabPsycho Posted - 1 day ago

$SNSE @BiotechValues I am working on another simulation...it takes a lot of time to not only do the simulation but to cobble together even just a low quality presentation...but I think I have some more details to show beyond their recent Nature paper. Doesn't mean diddly as far as predicting efficacy but may show additional basis for pH selectivity. @williams2020 @Selwot

intratio Posted - 1 day ago

https://www.intratio.com/stock-forecast/SNSE Sensei Biotherapeutics, Inc. The network has predicted this company s stock price will immediately and drastically decrease with a clear pessimistic long-term perspective $SNSE

PlannedTrading101 Posted - 2 days ago

$SNSE 🔥

BiotechValues Posted - 2 days ago

$SNSE heavy buy volume coming in. Top-line data likely next Thursday when abstract embargo ends

LabPsycho Posted - 2 days ago

$SNSE Maybe some decent volume coming back in today. @intratio "AI" prediction below likely to be wrong - again.

intratio Posted - 2 days ago

$SNSE https://www.intratio.com/stock-forecast/SNSE Sensei Biotherapeutics, Inc. Our AI concludes that this company s stock price will fall in the upcoming week and is facing massive downsides in the longer term

LabPsycho Posted - 3 days ago

$XLO $SNSE By my guess, * Both trading below cash; * XLO showing tumor shrinkage and deal with GILEAD; * SNSE has a very impressive recent publication in Nature Comm. and collaborations with NIH and Regeneron.

BiotechValues Posted - 3 days ago

$SNSE should be getting a conference call announcement in the coming days to announce the top-line data date (abstracts out next Thursday). Think the stock will spike violently on that press release

GreggTwits Posted - 3 days ago

$SNSE

LabPsycho Posted - 4 days ago

$SNSE IMO, a rather unimaginative and trite buy recommendation - I see nothing original by the Stephens analyst. How about something more speculative and fanciful like: *** $SNSE has at least two possible critical clinical updates by year end; *** Trading at a market cap significantly below cash; *** Possible surprise partnership with big pharma, i.e. current collaboration w/ Regeneron could be expanded; *** Possible expansion of their CRADA relationships with the U.S.A. government's National Institutes of Health; *** [long shot and even more speculative than the above] SNSE low float + cash with the possibility of encouraging clinical data update could be one of those 100M share /day trades seen in several other biotechs recently sending share price 4-6 fold in hours. Cons: Biotech is weak, going into typically weak season summer, money may be flowing out of the overall market, upcoming election uneasiness in overall market.

BiotechValues Posted - 4 days ago

$SNSE Stephens initiates at Overweight with $5 price target. Upcoming top-line data at ASCO, for anti-VISTA SNS-101, "can be an inflection point for the company"

LabPsycho Posted - 5 days ago

$SNSE @telomerase Just my opinion but I get a kick out of folks that like to buy a small / cheap biotech stock with high institutional ownership - If they already bought and the price is below $5 or so (down from the typical $75/sh in the past 2 yr)...what's gong to happen to the stock price when one or more of these institutions needs to unload? I think better to get in before the institutions rather than after because by then the major price appreciation has already occurred.

LabPsycho Posted - 5 days ago

$SNSE Last week's price movement and relatively low volume clean up / clean out the quick money followed by this morning's move up (so far) smells to me like a partnership deal could be in the works.

LabPsycho Posted - 1 week ago

$SNSE $JANX @BiotechValues Awesome set of posts and explanations and I greatly appreciate the graphics and highlighing for extra clarity. Separately, I am not sure I fully understand backfilling? Going back and giving previously treated lower dose patients a higher dose?

BiotechValues Posted - 1 week ago

$SNSE - $CTMX and $JANX started to backfill because of efficacy

BiotechValues Posted - 1 week ago

$SNSE There has to be a reason why the 15MG monotherapy dose was backfilled from 3 to 6 patients (as there were no DLTs). My guess is they saw anti-tumor activity or a response there, and went from 3 to 6 patients. They then decided to initiate dose expansion at 15MG for MSS CRC. From the Jan PR "Given the favorable data thus far, we are expanding the SNS-101 Phase 1/2 clinical trial to include additional patients in a more focused set of indications"

BiotechValues Posted - 1 week ago

$SNSE if you do the math, 18-20 out of 40 mono/ combo expansion cohort patients are MSS CRC. Last year $CGEM announced positive ph1 monotherapy data in gynecological and thus initiated dose expansion in endometrial + cervical. Very high chance $SNSE is seeing activity in MSS CRC

LabPsycho Posted - 1 week ago

$SNSE @elmono @BiotechValues In my opinion, Market makers use sector sympathy crashes (if you consider CTMX being up 50% in about a week a 'crash' ) coupled with a typical quarterly update for the biotech company of interest on the heels of 100-200% gain in a few weeks as an opportunity to parlay a good pants-ing of the stock to take out stop loss orders and gaslight existing longs to make you doubt your holding. $SNSE with a cash reservoir, and important read outs in the next few months, and a collaboration with Regeneron and the NIH I would say by year end downside / upside risk/ reward is -40% / 300% from here. All wild guesses of course. Good luck

LabPsycho Posted - 1 week ago

$SNSE @elmono You may be correct in your deductions and I have thought this about several other biotechs - higher dose needed. On the other hand this also looks like it could be the classic market makers shakeout trying to gaslight current longs to sell based on the good news and dropping the bid in sympathy with CTMX (CTMX different mechanism of action than SNSE drug by the way).

elmono Posted - 1 week ago

$SNSE dose escalation finished & expanding in the highest dose only & pre announcing testing possible further doses. I have a feeling they are not yet seeing the activity they are hoping to see 🤷‍♂️…..but what do I know 😁

LabPsycho Posted - 1 week ago

$SNSE Looks like taking out lots of stop loss orders put in by those up 100-200% in a few weeks. Possible classic low volume shake out before next leg up IMO

BiotechValues Posted - 1 week ago

$SNSE majority of run-up wiped out on no news. $CTMX was targeting a different target, with different science, and a way higher market cap. Absurd for the drop to be based one CTMX miss

BiotechValues Posted - 1 week ago

$SNSE FWIW, I expect them to announce a conference call or investor event ahead of ASCO to discuss anti-VISTA data. Email from IR:

LabPsycho Posted - 1 week ago

$SNSE @BiotechValues Nice call on the timing of Q1.

LabPsycho Posted - 1 week ago

$SNSE @DonCorleone77 There is great significance and impact of $SNSE recent Nature Communication peer reviewed publication detailing how SNS-101, a newly developed pH-selective VISTA antibody, addresses and potentially resolves challenges observed with previous VISTA antibodies.

DonCorleone77 Posted - 1 week ago

$SNSE Sensei Biotherapeutics reports Q1 EPS (32c), consensus (27c) Building upon our initial data for SNS-101, which we believe support a favorable and potentially best-in-class clinical safety and PK profile, we now look forward to sharing topline dose escalation data at ASCO in June and initial dose expansion data in the fourth quarter of this year, said John Celebi, President and Chief Executive Officer. Looking ahead, we are squarely focused on advancing patient enrollment in the dose expansion cohorts, which are intended to generate additional supportive data and optimize the Phase 2 trial design for SNS-101. With cash runway into the fourth quarter of 2025, we believe we are in a strong position to build on both our clinical momentum on behalf of the patients we aim to serve and our scientific advances, as illustrated by our recent publication in Nature Communications.

BiotechValues Posted - 1 week ago

$SNSE topline clinical data from SNS-101 anti-VISTA mono/combo study to be presented at ASCO. Enrollment in dose expansion arms continues in mono/combo. $2.32/share in cash as of March 31.